Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Changrui Guanchang San is a Traditional Chinese Medicine (TCM) formulation developed by Shanxi Zhendong Pharmaceutical for the treatment of chronic radiation proctitis. Administered as a retention enema, the drug is designed to alleviate symptoms such as rectal bleeding, pain, and tenesmus by promoting mucosal repair and reducing local inflammation. The formulation typically contains a mixture of herbal extracts, including *Sanguisorba officinalis* and *Bletilla striata*, which provide hemostatic and wound-healing properties. It has undergone Phase III clinical trials in China, demonstrating efficacy in improving the clinical symptoms and endoscopic appearance of the rectal mucosa in patients suffering from radiation-induced injury following pelvic malignancy treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Changrui Guanchang San.